SU711037A1 - Pyrido /2,3-e/-1,2,4-thiadiazine-1,1-dioxides possessing analgetic and antiinflammatory activity - Google Patents
Pyrido /2,3-e/-1,2,4-thiadiazine-1,1-dioxides possessing analgetic and antiinflammatory activity Download PDFInfo
- Publication number
- SU711037A1 SU711037A1 SU772449114A SU2449114A SU711037A1 SU 711037 A1 SU711037 A1 SU 711037A1 SU 772449114 A SU772449114 A SU 772449114A SU 2449114 A SU2449114 A SU 2449114A SU 711037 A1 SU711037 A1 SU 711037A1
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- pyrido
- thiadiazine
- dioxides
- antiinflammatory activity
- analgetic
- Prior art date
Links
- 230000003110 anti-inflammatory effect Effects 0.000 title claims description 5
- 230000000202 analgesic effect Effects 0.000 title claims description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 230000001760 anti-analgesic effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000000548 hind-foot Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- RMMXTBMQSGEXHJ-UHFFFAOYSA-N Aminophenazone Chemical compound O=C1C(N(C)C)=C(C)N(C)N1C1=CC=CC=C1 RMMXTBMQSGEXHJ-UHFFFAOYSA-N 0.000 description 1
- QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical compound CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 229960000212 aminophenazone Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000001350 orogenic effect Effects 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical group O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
рим в воде и этаноле при нагревании. Найдено, %: С 42,68; Н 3,67; N 21,35; C HyNgOjS. Вычислено, %: С 42,60; Н 3,60; N 21,30, ,63 (бутанолгвода:уксусна кислота - 4:1 si) .Rome in water and ethanol when heated. Found,%: C 42.68; H 3.67; N 21.35; C HyNgOjS. Calculated,%: C 42.60; H 3.60; N 21.30, 63 (butanol: aqueous acetic acid - 4: 1 si).
Исследовани биологической активности были проведены на белых машах и белых крысах линии Вистар при внутрибрюшинном введении.Studies of biological activity were carried out on white masks and white Wistar rats with intraperitoneal administration.
Дл оценки противовоспалительного действи была использована модель формалинового воспалени , дл чего в планетарный апоневроз задней лапы крысы вводили 2,5%-ный раствор формалина (0,1 мл). Величину отека задней лапы опЕюдел ли онкометрическим методом Л.С. Сал мона через 3 и 6 ч. после введени оркогенного агента. Испытуе- мые препараты вводили в дозе 50 мг/кг :(1/10 от ЛДдд) за 0,5 ч до и через 3 ч после введени формалина. Эталоном сравнени служит фенилбутазон (бутадион) в дозе 30 мг/кг.A formalin-inflammatory model was used to evaluate the anti-inflammatory effect, for which a 2.5% formalin solution (0.1 ml) was injected into the planetary aponeurosis of the hind paw of the rat. The value of the swelling of the hind paw was determined by the oncometric method LS Sal Mona 3 and 6 hours after the introduction of the orogenic agent. The tested drugs were administered at a dose of 50 mg / kg: (1/10 from LDDD) 0.5 hours before and 3 hours after the formalin was injected. The reference standard is phenylbutazone (butadione) at a dose of 30 mg / kg.
Дл оценки анальгетического действи была использована общеприн та методика гор чей пластинки (Эдди и Леймбах, 1953) . В качестве эталона дл сравнени анальгетической активности был использован амидопирин в дозе 100 мг/кг (1/3 от ДЦзо)The conventional hot plate technique was used to evaluate the analgesic effect (Eddie and Leimbach, 1953). Amidopyrine at a dose of 100 mg / kg (1/3 from DZZO) was used as a reference for comparison of analgesic activity.
Исследовани показа.ли, что испытанный препарат обладает противовоспалительной и анальгетической активностью , сопоставимой с эффектами примен емых в практике лекарственных веществ.Studies have shown that the tested drug has anti-inflammatory and analgesic activity comparable to the effects of medicinal substances used in practice.
Соединени 1 и П малотоксичны, ЛД50 500 мг/кг.Compounds 1 and P are of low toxicity, LD50 500 mg / kg.
Результаты испытаний, подтверждающие противовоспалительную и анальгетическую активность, представлены в таблице.The test results confirming the anti-inflammatory and analgesic activity are presented in the table.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU772449114A SU711037A1 (en) | 1977-02-01 | 1977-02-01 | Pyrido /2,3-e/-1,2,4-thiadiazine-1,1-dioxides possessing analgetic and antiinflammatory activity |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU772449114A SU711037A1 (en) | 1977-02-01 | 1977-02-01 | Pyrido /2,3-e/-1,2,4-thiadiazine-1,1-dioxides possessing analgetic and antiinflammatory activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SU711037A1 true SU711037A1 (en) | 1980-01-25 |
Family
ID=20694266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU772449114A SU711037A1 (en) | 1977-02-01 | 1977-02-01 | Pyrido /2,3-e/-1,2,4-thiadiazine-1,1-dioxides possessing analgetic and antiinflammatory activity |
Country Status (1)
| Country | Link |
|---|---|
| SU (1) | SU711037A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2307124C1 (en) * | 2006-05-24 | 2007-09-27 | Общество с ограниченной ответственностью "СУЛЬФОН" (ООО "Сульфон") | Bicyclic 1,4-piridotiazine-1,1-dioxides and method for production thereof |
| EA010308B1 (en) * | 2004-12-10 | 2008-08-29 | Ле Лаборатуар Сервье | Benzothiazine and benzothiadiazine derivatives, process for their preparation and pharmaceutical compositions containing them |
-
1977
- 1977-02-01 SU SU772449114A patent/SU711037A1/en active
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA010308B1 (en) * | 2004-12-10 | 2008-08-29 | Ле Лаборатуар Сервье | Benzothiazine and benzothiadiazine derivatives, process for their preparation and pharmaceutical compositions containing them |
| RU2307124C1 (en) * | 2006-05-24 | 2007-09-27 | Общество с ограниченной ответственностью "СУЛЬФОН" (ООО "Сульфон") | Bicyclic 1,4-piridotiazine-1,1-dioxides and method for production thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0189788B1 (en) | Synergistic combination of flupirtin and non-steroidal anti-phlogistics | |
| Perdue et al. | South American plants II: Taspine isolation and anti‐inflammatory activity | |
| US4016268A (en) | Method of combatting gastric ulceration | |
| FI74705C (en) | Process for the preparation of new crystalline benzothiazine dioxide salts. | |
| JPS6339567B2 (en) | ||
| Filderman et al. | Anti-inflammatory activity of the steroid alkaloid glycoside, tomatine | |
| SU711037A1 (en) | Pyrido /2,3-e/-1,2,4-thiadiazine-1,1-dioxides possessing analgetic and antiinflammatory activity | |
| Ghosh et al. | Inhibitory effect of a pyrrolidine alkaloid, crotalaburnine, on rat paw oedema and cotton pellet granuloma | |
| US3914253A (en) | 5-Oxo-6-substituted-cyclopent-{8 f{9 -indole-2-carboxylic acids | |
| EP0152868A2 (en) | Isoxazole derivatives, process for their preparation, and pharmaceuticals containing these compounds | |
| DE2719246A1 (en) | PIPERAZINE DERIVATIVES AND MEDICINAL PRODUCTS CONTAINING THEM | |
| JPH0368515A (en) | Antiallergic drug | |
| JPS63211269A (en) | 14-anisoylaconine and novel analgesic and anti-inflammatory drug containing said compound as active ingredient | |
| DE50006842D1 (en) | 4-BENZYLAMINOCHINOLINE CONJUGATES WITH GALLIC ACID AND THEIR HETEROANALOGS, METHOD FOR THE PRODUCTION THEREOF, MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS AND THE USE THEREOF | |
| CA1139670A (en) | Process and composition for reducing blood pressure in animals | |
| KAWAI et al. | Anti-inflammatory, analgesic and antipyretic activities of 6-chloro-5-cyclohexylindan-1-carboxylic acid (TAI-284) | |
| DE2621082A1 (en) | PIPERAZINE DERIVATIVE, THE PROCESS FOR ITS MANUFACTURING AND ITS USE AS A MEDICINAL PRODUCT | |
| EP0440098B1 (en) | Optically active derivative of d-2-(6-methoxy-2-naphthyl)-propionic acid and pharmaceutical compositions containing it | |
| FR2236488B1 (en) | ||
| RU2045268C1 (en) | Antihistamine and antiallergic agent and method for preparing of glutaminate of hinuclidise-3-diphenylcarbinol as solution for injections | |
| KR910016331A (en) | Ischemic Disease Drug | |
| AT331211B (en) | PROCESS FOR THE PRODUCTION OF NEW AMINOBENZYLAMINES AND THEIR ACID ADDITION SALTS | |
| AT331216B (en) | PROCESS FOR THE PRODUCTION OF NEW AMINOBENZYLAMINES AND THEIR ACID ADDITION SALTS | |
| RU2035906C1 (en) | Method for treating hepatic diseases of diverse sorts of genesis | |
| DE1695736A1 (en) | Process for the preparation of new piperonylpiperazine derivatives |